EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial ( BESST )

Henry P Parkman iD, Katherine P Yates, Irene Sarosiek, Robert S Bulat, Thomas L Abell, Kenneth L Koch, Braden Kuo, Madhusudan Grover iD, Gianrico Farrugia iD, Paul Silver, Amirah Abdullah, Alan H Maurer und 7 weitere

Alimentary Pharmacology & Therapeutics · 2023-06 · 57 (11) · 1272-1289

DOI: 10.1111/apt.17479 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 13.04.2023. Verfasst von Henry P Parkman und 18 weiteren Autor:innen. Beteiligte Einrichtung: Temple University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Buspirone, Gastroparesis. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. Buspirone, a 5‐HT 1 receptor agonist, may improve fundic accommodation.

Aim

To determine if buspirone treatment improves early satiety and postprandial fullness in patients with symptoms of gastroparesis.

Methods

This 4‐week multi‐centre clinical trial randomised patients with symptoms of gastroparesis and moderate‐to‐severe symptoms of fullness (Gastroparesis Cardinal Symptom Index [GCSI] early satiety/postprandial fullness subscore [ES/PPF]) to buspirone (10 mg orally) or placebo three times per day. The primary outcome was a change in the ES/PPF from baseline to 4 weeks. The primary analysis was per protocol intention‐to‐treat ANCOVA of between‐group baseline vs. 4‐week differences (DoD) in ES/PPF adjusted for baseline ES/PPF. Results are reported using both nominal and Bonferroni (BF) p values. Results and conclusions Ninety‐six patients (47 buspirone, 49 placeboes; 92% female, 50% delayed gastric emptying, 39% diabetic) were enrolled. There was no between‐groups difference in the 4‐week ES/PPF primary outcome: −1.16 ± 1.25 (SD) on buspirone vs −1.03 ± 1.29 (SD) on placebo (mean DoD: −0.11 [95% CI: −0.68, 0.45]; p = 0.69). Buspirone performed better than placebo in patients with severe‐to‐very severe bloating at baseline compared to patients with none to moderate: (ES/PPF DoD = −0.65 vs. 1.58, p TX*GROUP = 0.003; p BF = 0.07). Among individual GCSI symptoms, only bloating appeared to improve with buspirone vs. placebo.

Conclusions

Patients with moderate‐to‐severe early satiety/postprandial fullness and other symptoms of gastroparesis did not benefit from buspirone treatment to improve the ES/PPF primary outcome compared with placebo. There was a suggestion of the benefit of buspirone in patients with more severe bloating. Trial Registration: ClinicalTrials.gov NCT0358714285.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuspironeGastroparesisHumansFemaleMaleDouble-Blind MethodGastric Emptying

Substanzen

Buspirone

Autor:innen und Institutionen

  • Temple University, Philadelphia, Pennsylvania, USA.
  • Johns Hopkins University, Baltimore, Maryland, USA.
  • Texas Tech University Health Sciences Center, El Paso, Texas, USA.
  • University of Louisville, Louisville, Kentucky, USA.
  • Wake Forest University, Winston-Salem, North Carolina, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Henry P Parkman, Madhusudan Grover, Gianrico Farrugia

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Parkman, H. P., Yates, K. P., Sarosiek, I., Bulat, R. S., Abell, T. L., Koch, K. L., Kuo, B., Grover, M., Farrugia, G., Silver, P., Abdullah, A., Maurer, A. H., Malik, Z., Miriel, L. A., Tonascia, J., Hamilton, F., Pasricha, P. J., McCallum, R. W., & NIDDK Gastroparesis Clinical Research Consortium (2023). Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial ( BESST ). Alimentary Pharmacology & Therapeutics, 57(11), 1272-1289. https://doi.org/10.1111/apt.17479

Vancouver

Parkman HP, Yates KP, Sarosiek I, Bulat RS, Abell TL, Koch KL, et al. Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial ( BESST ). Alimentary Pharmacology & Therapeutics. 2023;57(11):1272-1289. doi:10.1111/apt.17479

BibTeX
@article{Parkman2023,
  author = {Parkman, Henry P and Yates, Katherine P and Sarosiek, Irene and Bulat, Robert S and Abell, Thomas L and Koch, Kenneth L and Kuo, Braden and Grover, Madhusudan and Farrugia, Gianrico and Silver, Paul and Abdullah, Amirah and Maurer, Alan H and Malik, Zubair and Miriel, Laura A and Tonascia, James and Hamilton, Frank and Pasricha, Pankaj J and McCallum, Richard W and NIDDK Gastroparesis Clinical Research Consortium, NIDDK Gastroparesis Clinical Research Consortium},
  title = {Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial ( BESST )},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {11},
  pages = {1272--1289},
  doi = {10.1111/apt.17479}
}
Kostenlos starten →